BDR Pharma launches BDENZA (Enzalutamide), the world’s first oral solution for prostate cancer management. BDENZA is priced at Rs 27,000 for 150mL, offering reduced dosing frequency, toxicity, and side effects compared to existing oral formulations. The innovative formulation improves patient compliance with its palatable sugar-free taste and affordability. It also allows for dose adjustment based on consumption volume, addressing the challenges faced by patients. Prostate cancer is a growing concern, with an estimated 375,000 deaths, according to the WHO.
Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News